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Abstract
Esophageal adenocarcinoma (EAC) is a poor prognosis cancer type with rapidly rising incidence. 
Our understanding of genetic events that drive EAC development is limited, and there are few 
molecular biomarkers for prognostication or therapeutics. Using a cohort of 551 genomically 
characterized EACs with matched RNA-seq, we discover 77 EAC driver genes and 21 non-coding 
driver elements. We identify a mean of 4.4 driver events per tumor, derived more commonly from 
mutations rather than copy number alterations, and compare these mutations to the exome-wide 
mutational excess using dN/dS calculations. We observe mutual exclusivity or co-occurrence of 
events within and between a number of dysregulated EAC pathways, suggestive of strong 
functional relationships. Poor prognostic indicators (SMAD4, GATA4) are verified in independent 
cohorts with significant predictive value. Over 50% of EACs contain sensitizing events for 
CDK4/6 inhibitors, which are highly correlated with clinically relevant sensitivity in a panel EAC 
cell lines and organoids.
Esophageal cancer is the eighth most common form of cancer world-wide and the sixth most 
common cause of cancer related death1. Esophageal adenocarcinoma (EAC) is the 
predominant subtype in the west, and incidence has been rapidly rising2. EAC is a highly 
aggressive neoplasm, usually presenting at a late stage, and is generally resistant to 
chemotherapy, leading to five-year survival rates below 15%3. It is characterized by very 
high mutation rates in comparison to other cancer types4 but also, paradoxically, by a 
paucity of recurrently mutated genes. EAC displays dramatic chromosomal instability and 
thus may be classified as a C-type neoplasm, which may be driven mainly by structural 
variation rather than mutations5,6. Currently, our understanding of precisely which genetic 
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events drive the development of EAC is limited, and consequentially there is a paucity of 
molecular biomarkers for prognosis or targeted therapeutics available.
Methods to differentiate driver mutations from passenger mutations use features associated 
with known drivers to detect regions of the genome in which mutations are enriched for 
these features7. The simplest of these features is the tendency of a mutation to co-occur with 
other mutations in the same gene at a high frequency, as detected by MutSigCV8. 
MutSigCV has identified 12 known cancer genes as EAC drivers (TP53, CDKN2A, 
SMAD4, ARID1A, ERBB2, KRAS, PIK3CA, SMARCA4, CTNNB1, ARID2, PBRM1 and 
FBXW7)6,9,10. The PCAWG ICGC analysis also identified a significantly mutated 
enhancer associated with TP53TG111. However, these analyses leave most EAC cases with 
only one known driver mutation, usually TP53. Equivalent analyses in other cancer types 
have identified three or four drivers per case12,13. Similarly, detection of copy number 
driver events in EAC has relied on identifying regions of the genome recurrently deleted or 
amplified, as detected by GISTIC9,14–17. However, GISTIC often identifies relatively large 
regions of the genome, with little indication of which specific gene-copy number aberrations 
(CNAs) may actually confer a selective advantage. There are also several non-selection 
based mechanisms that can cause recurrent CNAs, such as genomic fragile sites, which have 
not been well differentiated from selection-based CNAs18. Epigenetic events, for example 
methylation, may also be important sources of driver events in EAC but are much more 
difficult to assess formally for selection.
To address these issues, we accumulated a cohort of 551 genomically characterized EACs 
using our esophageal ICGC project, which have high quality clinical annotation, associated 
whole genome sequencing (WGS) and RNA-seq on cases with sufficient material. We 
augmented our ICGC WGS cohort with publicly available whole exome19 and whole 
genome sequencing20 data and applied a number of complementary driver detection 
methods to produce a comprehensive assessment of mutations and CNAs under selection in 
EAC. We use these events to define functional cell processes that have been selectively 
dysregulated in EAC and identify novel, verifiable and clinically relevant biomarkers for 
prognostication. Finally, we have used this compendium of EAC driver events to provide an 
evidence base for targeted therapeutics, which we have tested in vitro.
Results
A compendium of EAC driver events and their functional impact
In 551 EACs, we identified a total of 11,813,333 single nucleotide variants (SNVs) and 
small insertions or deletions (Indels), with a median of 6.4 such mutations/Mb 
(Supplementary Fig. 1), and 286,965 copy number aberrations (CNAs). We also identified 
134,697 structural variants (SVs) in WGS cases. We use several complementary driver 
detection tools to detect driver-associated features in mutations and CNAs (Fig. 1a). Each 
tool underwent quality control to ensure reliability of results (see Methods). These features 
include highly recurrent mutations within a gene (dNdScv21, ActivedriverWGS22, 
MutSigCV28), high functional impact mutations within a gene (OncodriveFM23, 
ActivedriverWGS22), mutation clustering (OncodriveClust24, eDriver25 and eDriver3D26) 
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and recurrent amplification or deletion of genes (GISTIC14) undergoing concurrent over or 
under-expression (see Methods) (Fig. 1a)7.
These complementary methods produced highly significant agreement in calling EAC driver 
genes, particularly within the same feature-type (Supplementary Fig. 2), and on average 
more than half of the genes identified by one feature were also identified by other features 
(Fig. 1b). In total, 76 EAC driver genes were discovered, 71% of which have not been 
detected in EAC previously9,10,15–17,19 and 69% of which are known drivers in pan-
cancer analyses21,27,28. To detect driver elements in the non-coding genome, we used 
ActiveDriverWGS22, a recently benchmarked29 method using both functional impact and 
recurrence to determine driver status (Fig. 1c and Supplementary Fig. 3). We discovered 21 
non-coding driver elements using this method. We have recovered several known non-coding 
driver elements from the pan-cancer PCAWG analysis11, including the enhancer on 
chromosome 7 linked to TP53TG1 previously identified in EAC and the promoter/5’UTR 
regions of PTDSS1 and WRD74 found in other cancer types. We also identified novel non-
coding cancer driver elements, including in the 5’UTR of MMP24 and promoters of two 
related histones (HIST1H2BO and HIST1H2AM).
EAC is notable among cancer types for harboring a high degree of chromosomal 
instability20. Using GISTIC, we identified 149 recurrently deleted or amplified loci across 
the genome (Fig. 2a, and Supplementary Tables 1 and 2). To determine which genes within 
these loci confer a selective advantage when they undergo CNAs, we use a subset of 116 
cases with matched RNA-seq to detect genes in which homozygous deletion or amplification 
causes a significant under or over-expression, respectively (Supplementary Note and 
Supplementary Tables 3-6). The majority of genes in these regions showed no significant 
copy number associated expression change (74%), although work in larger cohorts suggests 
we may be underpowered to detect small expression changes30. We observed highly 
significant expression changes in 17 known cancer genes within GISTIC loci such as 
ERBB2, KRAS and SMAD4, which we designate high-confidence EAC drivers (see 
Methods). We also found five tumor suppressor genes where copy number loss was not 
necessarily associated with expression modulation but tightly associated with presence of 
mutations leading to LOH, for example ARID1A and CDH11.
In a subset of GISTIC loci, we observed extremely high copy number amplification, 
commonly greater than 100 copies, and these events were highly enriched in recurrently 
amplified regions containing driver genes rather than those which appear to contain only 
passengers (ploidy adjusted copy number >10, two-sided Wilcoxon test, P = 4.97 x 10-8) 
(Supplementary Fig. 4). We use ploidy adjusted copy number to define amplifications as it 
produces superior correlation with expression data than absolute copy number alone. Ploidy 
of our samples varies from 1.4-6.2 (median 2.8), and hence ploidy adjusted copy number of 
>10 cut off translates into >14-62 absolute copies (on average 28 copies). To discern a 
mechanism for these ultra-high amplifications, we assessed structural variants (SVs) 
associated with these events. For many of these events, the extreme amplification was 
produced largely from a single copy number step, the edges of which were linked by 
structural variants with ultra-high read support. Two examples are shown in Figure 2b, and 
further randomly selected examples in Supplementary Figure 5. In the first example, 
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circularization and amplification initially occurred around MYC but subsequently 
incorporated ERBB2 from an entirely different chromosome, and in the second, an inversion 
was followed by circularization and amplification of KRAS. Such a pattern of 
extrachromosomal amplification via double minutes has been previously noted in EAC20 
and other neoplasms31, and hence we refer to this amplification class with ultra-high 
amplification (ploidy adjusted copy number >10) as ‘extrachromosomal-like’.
We found that extrachromosomal-like amplifications had extreme and highly penetrant 
effects on expression, while moderate amplification (ploidy adjusted copy number > 2 but < 
10) and homozygous deletion had highly significant (Wilcoxon test, two-sided, P = 9.62 x 
10-16 and P = 7.64 x 10-11, respectively) but less dramatic effects on expression with a lower 
penetrance (Fig. 2c). This lack of penetrance was associated with low cellularity as 
calculated by ASCAT (Wilcoxon test, two-sided, overexpression cut off = 2.5x normalised 
expression, P = 0.011) in non-extrachromosomal-like amplified cases but also likely reflects 
that specific genetic rearrangements, not just gene-dosage, can modulate expression. We also 
detected several cases of overexpression or complete expression loss without associated 
copy number changes, reflecting non-genetic mechanisms for driver dysregulation. One case 
overexpressed ERBB2 at 28-fold median expression but had entirely diploid copy number in 
and surrounding ERBB2, and a second case lost SMAD4 expression (0.008-fold median 
expression) despite possessing five copies of SMAD4.
Landscape of driver events in EAC
The overall landscape of driver gene mutations and copy number alterations per case is 
depicted in Figure 3a. These comprise both oncogenes and tumor suppressor genes activated 
or repressed via different mechanisms. Passenger mutations occur by chance in most driver 
genes. To quantify this, we used the observed:expected mutation ratios (calculated by 
dNdScv) to estimate the percentage of driver mutations in each gene and in different 
mutation classes. For many drivers, only specific mutation classes appear to be under 
selection. Many tumor suppressor genes (ARID2, RNF43, ARID1B for example) are only 
under selection for truncating mutations, i.e. splice site, nonsense and frameshift Indel 
mutations, but not missense mutations, which are passengers. However, oncogenes, like 
ERBB2, only contain missense drivers that form clusters to activate gene function in a 
specific manner. Where a mutation class is <100% driver mutations, mutational clustering 
can help us define the driver vs. passenger status of a mutation (Supplementary Fig. 6). 
Mutational hotspots in EAC or other cancer types32 (Supplementary Table 7 and 
Supplementary Data) are indicated in Figure 3a. Novel EAC drivers of particular interest 
include B2M, a core component of the MHC class I complex and a marker of acquired 
resistance to immunotherapy33, MUC6, a secreted glycoprotein involved in gastric acid 
resistance, and ABCB1, a channel pump protein associated with multiple instances of drug 
resistance34. We note that several of these drivers have been previously associated with 
gastric and colorectal cancer (Supplementary Table 8)13,35.
The identification of driver events provides rich information about the molecular history of 
each EAC tumor. We detect a median of five events in driver genes per tumor (IQR = 3-7, 
mean = 5.6), and only a very small fraction of cases has no such events detected (6 cases, 
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1%). When we remove the predicted percentage of passenger mutations using 
observed:expected mutation ratios calculated by dNdScv, one of the driver gene detection 
methods used, we find a mean of 4.4 true driver events per case. These derive more 
commonly from mutations than copy number events (Fig. 3b and Supplementary Table 9). 
Using hierarchal clustering of drivers, we noted that TP53 mutant cases had significantly 
more copy number drivers (Wilcoxon test, two-sided, P = 0.0032, Supplementary Figs. 7 and 
8). dNdScv also analyses the genome-wide excess of non-synonymous mutations based on 
dN/dS ratios to assess the mean number of exonic driver mutations per case. This is 
calculated at 5.4 (95% CIs: 3.5-7.3) in comparison to a mean excess of 2.7 driver mutations 
in specific EAC driver genes, suggesting further low frequency driver genes are yet to be 
discovered in EAC.
To better understand the functional impact of driver mutations, we analyzed expression of 
driver genes with different mutation types and compared their expression to normal tissue 
RNA (Fig. 3c and Supplementary Fig. 10). Since surrounding squamous epithelium is a 
fundamentally different tissue from which EAC does not directly arise, we have used 
duodenum and gastric cardia samples as gastrointestinal phenotype controls, likely to be 
similar to the, as yet unconfirmed, tissue of origin in EAC. A large number of driver genes 
have upregulated expression in comparison to normal controls; for example, TP53 has 
upregulated RNA expression in wild-type tumor tissue and in cases with non-truncating 
mutations but RNA expression is lost upon gene truncation. In depth analysis of different 
TP53 mutation types reveals significant heterogeneity within non-truncating mutations 
(Supplementary Fig. 9). Normal tissue expression of CDKN2A suggests that CDKN2A is 
generally activated in EAC, likely due to genotoxic or other cancer-associated cellular 
stresses36, and returns to physiologically normal levels when deleted. Heterogeneous 
expression in wild-type CDKN2A cases suggests a different mechanism of inhibition, 
perhaps methylation, in some cases. Overexpression of some oncogenes occurs without 
genomic aberrations, such as MYC, which is overexpressed in MYC-wild-type EACs 
relative to normal tissues (Fig. 3c). A smaller number of driver genes are downregulated in 
EACs without genomic aberrations. 3/4 of these genes (GATA4, GATA6 and MUC6) are 
involved in the differentiated phenotype of gastrointestinal tissues and may be lost with 
tumor de-differentiation.
Dysregulation of specific pathways and processes in EAC
It is known that selection preferentially dysregulates certain functionally related groups of 
genes and biological pathways in cancer37. This phenomenon is highly evident in EAC, as 
shown in Figure 4, which depicts the functional relationships between EAC drivers 
(Supplementary Note). While TP53 is the dominant driver in EAC, 28% of cases remain 
TP53 wild-type. MDM2 is a E3 ubiquitin ligase that targets TP53 for degradation. Its 
selective amplification and overexpression is mutually exclusive with TP53 mutation, 
suggesting it can functionally substitute the effect of TP53 mutation via its degradation. 
Similar mutually exclusive relationships are observed between KRAS and ERBB2, GATA4 
and GATA6, and cyclin genes (CCNE1, CCND1 and CCND3). Activation of the Wnt 
pathway occurs in 19% of cases either by mutation of phospho-residues at the N terminus of 
β-catenin, which prevent degradation, or loss of Wnt destruction complex components like 
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APC. Many different chromatin modifying genes, often belonging to the SWI/SNF complex, 
are also selectively mutated (28% of cases). In contrast to other pathways, SWI/SNF genes 
are co-mutated significantly more often than we would expect by chance (Fisher’s exact test, 
two-sided, q < 0.05 for each gene; see Methods), suggesting these mutations are synergistic. 
We also assessed mutual exclusivity and co-occurrence in genes in different pathways and 
between pathways themselves (Fig. 4b). Of particular note are co-occurring relationships 
between TP53 and MYC, GATA6 and SMAD4, and Wnt and immune pathways, as well as 
mutually exclusive relationships between ARID1A and MYC, gastrointestinal (GI) 
differentiation and RTK pathways, and SWI-SNF and DNA damage response pathways. We 
were able to confirm some of these relationships in independent cohorts in different cancer 
types (Supplementary Table 10), suggesting some of these may be pan-cancer phenomenon. 
Wnt dysregulation was associated with hyper-mutated cases (> 500 exonic SNVs or Indels, 
Fisher’s exact test, two-sided, P = 2.98 x 10-5, OR = 9.3), as was mutation in immune 
pathway genes (B2M and JAK1, > 500 exonic SNVs or Indels, Fisher’s exact test, two-
sided, P = 6.27 x 10-6, OR = 35.7).
EAC driver events correlate with clinical phenotype
Events undergoing selection during cancer evolution influence tumor biology and thus 
impact tumor aggressiveness, response to treatment, and patient prognosis, as well as other 
clinical parameters.
Univariate Cox regression was performed for events in each driver gene with driver events 
occurring in greater than 5% of EACs after passenger removal to detect prognostic 
biomarkers (Fig. 5a). Events in two genes conferred significantly poorer prognosis after 
multiple hypothesis correction: GATA4 amplification (HR = 0.54, 95% CI = 0.38–0.78, P = 
0.0008) and SMAD4 mutation or homozygous deletion (HR = 0.60, 95% CI = 0.42–0.84, P 
= 0.003), which were present in 31% of EACs (Fig. 5b). Both genes remained significant in 
multivariate Cox regression, including pathological TNM staging, resection margin, curative 
vs. palliative treatment intent, and differentiation status (GATA4, HR adjusted = 0.47, 95% 
CIs adjusted = 0.29–0.76, P = 0.002; SMAD4, HR adjusted = 0.61, 95% CI adjusted = 0.40–
0.94, P = 0.026) (Fig. 5b, Supplementary Fig. 11). We validated the poor prognostic impact 
of SMAD4 events in an independent TCGA gastroesophageal cohort (HR = 0.58, 95% CI = 
0.37–0.90, P = 0.014) (Fig. 5c), and we also found GATA4 amplifications were prognostic in 
a cohort of TCGA pancreatic cancers (HR = 0.38, 95% CI = 0.18–0.80, P = 0.011) (Fig. 5d), 
the only available cohort containing a feasible number of GATA4 amplifications. The 
prognostic impact of GATA4 has been suggested in previously published independent EAC 
cohort16, although it did not reach statistical significance after FDR correction, and SMAD4 
expression loss has been previously linked to poor prognosis in EAC38. We also noted stark 
survival differences between cases with SMAD4 events and cases in which TGFβ receptors 
were mutated (Fig. 5e, HR = 5.6, 95% CI = 1.7–18.2, P = 0.005), in keeping with the 
biology of the TGFβ pathway, where non-SMAD TGFβ signalling is known to be 
oncogenic39.
In additional to survival analyses, we also assessed driver gene events for correlation with 
various other clinical factors, including differentiation status, sex, age and treatment 
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response. We found Wnt pathway mutations had a strong association with well differentiated 
tumours (P = 0.001, OR = 2.9, Fisher’s test, two-sided, see Methods; Fig. 5f). Female cases 
(n = 81) were enriched for KRAS mutation (P = 0.001, Fisher’s exact test, two-sided) and 
TP53 wild-type status (P = 0.006, Fisher’s exact test, two-sided) (Fig. 5g). This is of 
particular interest given the male predominance of EAC3.
Targeted therapeutics using EAC driver events
To investigate whether driver events in particular genes and/or pathways might sensitize 
EAC cells to certain targeted therapeutic agents, we used the Cancer Biomarkers database40. 
We calculated the percentage of our cases that contain EAC-driver biomarkers of response to 
each drug class in the database (Fig. 6a, and full data in Supplementary Table 11). Aside 
from TP53, which has been problematic to target clinically so far, we found a number of 
drugs with predicted sensitivity in >10% of EACs, including EZH2 inhibitors for some 
SWI/SNF mutant cancers (23%, and 28% including all SWI/SNF EAC drivers), and BET 
inhibitors, which target KRAS activated and MYC amplified cases (25%). However, by far 
the most significantly effective drug was predicted to be CDK4/6 inhibitors, where >50% of 
cases harbored sensitivity causing events in the receptor tyrosine kinase (RTK) and core cell 
cycle pathways (e.g. in CCND1, CCND3 and KRAS).
To verify that these driver events would also sensitize EAC tumors to such inhibitors, we 
used a panel of 13 EAC or Barrett’s high grade dysplasia cell lines that have undergone 
whole genome sequencing41 and assessed them for presence of EAC driver events (Fig. 6b). 
The mutational landscape of these lines was broadly representative of EAC tumors. We 
found that the presence of cell cycle and or RTK activating driver events was highly 
correlated with response to two FDA approved CDK4/6 inhibitors, Ribociclib and 
Palbociclib, and several cell lines were sensitive below maximum tolerated blood 
concentrations in humans (Fig. 6b, Supplementary Table 12, and Supplementary Fig. 12)42. 
Such EAC cell lines had comparable sensitivity to T47D, which is derived from an ER-
positive breast cancer, where CDK4/6 inhibitors have been FDA approved. We noted three 
cell lines that were highly resistant, with little drug effect even at 4,000 nM concentrations, 
similar to a known Rb mutant resistant line breast cancer cell line (MDA-MB-468). Two of 
these three cell lines harbor amplification of CCNE1, which is known to drive resistance to 
CDK4/6 inhibitors by bypassing CDK4/6 and causing Rb phosphorylation via CDK2 
activation43. To verify these effects in a more representative model of EAC, we treated three 
whole genome sequenced EAC organoid cultures44 with Palbociclib and Ribociclib as well 
as a more recently approved CDK4/6 inhibitor, Abemaciclib. As was observed in cell lines, 
cell cycle and RTK driver events were present only in the more sensitive organoids and 
CCNE1 activation in the most resistant (Fig. 6c).
Discussion
We present here a detailed catalog of coding and non-coding genomic events that have been 
selected for during the evolution of esophageal adenocarcinoma. These events have been 
characterized in terms of their relative impact, related functions, mutual exclusivity and co-
occurrence and expression in comparison to normal tissues. We have used this set of 
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biologically important gene alterations to identify prognostic biomarkers and actionable 
genomic events for personalized medicine.
While clinical annotation and matched RNA data is a strength of this study, in some cases 
we may have been unable to assess selected variants expression changes that were detected 
in the full 551 cohort due to lack of representation RNA matched sub-cohort. Despite 
rigorous analyses to detect selected events, assessment of the global excess of mutations by 
dNdScv suggests that we are unable to detect all mutations selected in EAC, similar to many 
other cancer types21. All driver gene detection methods that we have used rely on driver 
mutation re-occurrence in a genomic region to some degree. Many of these undetected driver 
mutations are hence likely to be spread across a large number of genes, whereby each is 
mutated at very low frequency across EAC patients. This tendency for low frequency EAC 
drivers may be responsible for the low yield of MutSigCV in previous cohorts and may 
suggests that C-type cancers such as EAC are not less ‘mutation-driven’ than M-type 
cancers but rather that their mutational drivers are spread across a larger number of genes5. 
Copy number driver gene identification is even more challenging due to the large size and 
lower frequency of these events, and hence it is also possible that there are significantly 
more EAC copy number drivers yet to discovered, possibly already identified as candidates 
here.
While a number of previous reports have attempted to detect EAC drivers, they have had a 
limited yield per case. The first such study19 used methods that, despite being well regarded 
at the time, were subsequently discredited8. Since then, a number of reports, including our 
own, on medium and large cohort sizes using MutSigCV9,10,17 were only able to detect a 
small number of mutational driver genes (7, 5 and 15 in each study). By using both a large 
cohort and more comprehensive methodologies, we have significantly increased this figure 
to 66 mutational driver genes (excluding copy number drivers). Detection of driver CNAs 
has previously relied on GISTIC to detect recurrently copy number aberrant regions9,14–17, 
but no analyses have been performed to determine which genes in these large regions are 
true drivers. Many of the genes annotated by such papers are unlikely to be copy number 
drivers due to their lack of expression modulation with CNAs (e.g. YEATS4 and MCL1), the 
role of recurrent heterozygous losses to drive LOH in some mutational drivers (ARID1A and 
CDH11) or their association with fragile sites (PDE4D, WWOX, FHIT). Conversely, we 
have been able to identify novel EAC copy number drivers (e.g. CCND3, AXIN1, PPM1D 
and APC).
We have noted a three-way association between hyper-mutation, Wnt activation and loss of 
immune signalling genes such as B2M. MSI-driven hyper-mutation has been previously 
associated with higher immune activity45,46. However, Wnt dysregulation and mutation of 
immune pathway genes such as B2M33 have been previously linked to immune escape47, 
suggesting this may be an acquired mechanism to prevent immune surveillance caused by 
hyper-mutation.
Functional characterization of many of the driver genes described is needed to understand 
why they are advantageous to EAC tumors and how they modify EAC biology. Biological 
pathways and processes that are selectively dysregulated deserve particular attention in this 
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regard, as do the gene pairs or groups with mutually exclusive or co-occurring relationships 
such as MYC and TP53 or SWI/SNF factors, suggestive of particular functional 
relationships. Prospective clinical work to verify and implement SMAD4 and GATA4 
biomarkers in this study would be worthwhile. While EAC is a poor prognosis cancer type, 
significant heterogeneity of survival outcome makes triaging patients in treatment groups an 
important part of clinic practice, which could be improved using better prognostication. A 
number of targeted therapeutics may provide clinic benefit to EAC cases based on their 
individual genomic profile. In particular, CDK4/6 inhibitors deserve considerable attention 
as an option for EAC treatment as they are, by a significant margin, the treatment to which 
the most EACs harbor sensitivity-causing driver events, excluding TP53 as an unlikely 
therapeutic biomarker. Previous work has noted activity of the CDK4/6 inhibitor Palbociclib 
in a small number of EAC cell lines48, but biomarkers were not investigated. The extensive 
in vitro validation of identified biomarkers for CDK4/6 inhibitors in EAC across 16 cell 
lines and organoids is persuasive of possible clinical benefit using a targeted approach.
In summary, this work provides a detailed compendium of mutations and copy number 
alterations undergoing selection in EAC, which have clinically relevant impact on tumor 
behaviour. This comprehensive study provides us with useful insights into the nature of EAC 
tumors and should pave the way for evidence based clinical trials in this poor prognosis 
disease.
Methods
Cohort, sequencing and calling of genomic events
379 cases (69%) of our EAC cohort were derived from the esophageal adenocarcinoma 
WGS ICGC study, for which samples are collected through the UK wide OCCAMS 
(Oesophageal Cancer Classification and Molecular Stratification) consortium. The 
procedures for obtaining the samples, quality control processes, extractions and whole 
genome sequencing are as previously described17. Strict pathology consensus review was 
observed for these samples with a 70% cellularity requirement before inclusion. 
Comprehensive clinical information was available for the ICGC-OCCAMS cases 
(Supplementary Table 13). In addition, previously published samples were included in the 
analysis from Dulak et al.19 (149 WES; 27%) and Nones et al.20 (22 WGS samples; 4%) to 
total 551 genome characterized EACs. RNA-seq data was available from our ICGC WGS 
samples (116/379). BAM files for all samples (include those from Dulak et al.19 and Nones 
et al.20) were run through our alignment (BWA-MEM), mutation (Strelka), copy number 
(ASCAT) and structural variant (Manta) calling pipelines, as previously described17. Our 
methods were benchmarked against various other available methods and have among the 
best sensitivity and specificity for variant calling (ICGC benchmarking exercise49,50). Cell 
lines were whole genome sequenced at 30X coverage with 150bp paired end reads on an 
Illumina Hiseq4000. Copy number calling was performed by Freec as previously 
described41. Mutations were called by GATK as previously described41, filtered for 
germline variants in the 1000 genomes project and any known oncogenic hotspots32 were 
recovered. Amplifications were defined as genes with 2x the median copy number of the 
host chromosome or greater.
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Total RNA was extracted using All Prep DNA/RNA kit from Qiagen, and the quality was 
checked on Agilent 2100 Bioanalyzer using RNA 6000 nano kit (Agilent). Qubit High 
sensitivity RNA assay kit from Thermo Fisher was used for quantification. Libraries were 
prepared from 250 ng RNA, using TruSeq Stranded Total RNA Library Prep Gold (Ribo-
zero) kit, and ribosomal RNA (nuclear, cytoplasmic and mitochondrial rRNA) was depleted, 
whereby biotinylated probes selectively bind to ribosomal RNA molecules forming probe-
rRNA hybrids. These hybrids were pulled down using magnetic beads and rRNA depleted 
total RNA was reverse transcribed. The libraries were prepared according to Illumina 
protocol51. Paired end 75-bp sequencing on HiSeq4000 generated the paired end reads. For 
normal expression controls, we chose gastric cardia tissue, from which some hypothesize 
Barrett’s esophagus may arise, and duodenum which contains intestinal histology, including 
goblet cells, which mimics that of Barrett’s esophagus. We did not use Barrett’s esophagus 
tissue itself as a normal control given the heterogeneous and plentiful phenotypic and 
genomic changes that it undergoes early in its pathogenesis.
Analyzing EAC mutations for selection
To detect positively selected mutations in our EAC cohort, a multi-tool approach across 
various selection related ‘features’ (recurrence, functional impact, clustering) was 
implemented in order to provide a comprehensive analysis. This is broadly similar to several 
previous approaches7,11. dNdScv21, MutSigCV8, e-Driver25, ActivedriverWGS22 and e-
Driver3D26 were run using the default parameters. To run OncodriverFM23, Polyphen52 
and SIFT53 were used to score the functional impact of each missense non-synonymous 
mutation (from 0 non-impactful to 1 highly impactful); synonymous mutations were given a 
score of 0 impact, and truncating mutations (nonsense and frameshift mutations) were given 
a score of 1. Any gene with less than 7 mutations, unlikely to contain detectable drivers 
using this method, was not considered to decrease the false discovery rate (FDR). 
OncodriveClust was run using a minimum cluster distance of 3, minimum number of 
mutations for a gene to be considered of 7 and with a stringent probability cut off to find 
cluster seeds of P = 1 x 10-13 to prevent infiltration of large numbers of, likely, false positive 
genes. For all tool outputs, we undertook quality control including Q-Q plots to ensure no 
tool produces inflated q-values and each tool produced at least 30% known cancer genes. 
Two tools were removed from the analysis due to failure for both of these parameters at 
quality control in our hands (Activedriver54 and Hotspot32). For three of the QC-approved 
tools (dNdScv, OncodriveFM, MutSigCV) where this was possible, we also undertook an 
additional FDR reducing analysis by re-calculating q values based on analysis of known 
cancer genes only21,27,28 as has been previously implemented21,55. Significance cut offs 
were set at q < 0.1 for coding genes. Tool outputs were then put through various filters to 
remove any further possible false positive genes. Specifically, genes where <50% of EAC 
cases had no expression (TPM<0.1) in our matched RNA-seq cohort were removed and, 
using dNdScv, genes with no or only a small mutation excess (observed: expected ratio > 
1.5:1) of any single mutation type were also removed. We also removed mitochondrial genes 
two (MT-MD2, MT-MD4) that were highly enriched for truncating mutations and were 
frequently called in OncodriveFM as well as other tools. This is may be due to the different 
mutational dynamics caused by ROS from the mitochondrial electron transport chain and the 
high number of mitochondrial genomes per cell, which enables significantly more 
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heterogeneity. These factors prevent the tools used from calculating an accurate null model 
for these genes, but they may be worthy of functional investigation. ActiveDriverWGS 
calculates an expected background mutation rate based on mutation rates of local, adjacent 
sequence for each tested element while correcting for the differential mutation rates within 
each trinucleotide context. It thus tests observed mutation rates against this predicted 
background for each element. ActiveDriverWGS also detects elements with mutations 
enriched in binding site regions (high impact). For non-coding elements called by 
ActivedriverWGS, filtering for expression or dN/dS was not possible, and despite recent 
benchmarking29, such methods are not so well established. Hence we took a more cautious 
approach with general significance cut offs of q < 0.001 and q < 0.1 for previously identified 
elements in other cancer types11. q values were not recalculated for previously identified 
elements alone like with coding genes, but the q < 0.1 cut off was calculated based on P 
values for all assessed elements. To calculate exome-wide mutational excess, hyper-mutated 
cases (>500 exonic mutations) were removed and the global non-synonymous dN/dS ratios 
were applied to all dNdScv annotated mutations excluding “synonymous” and “no SNV” 
annotations as described in Martincorena et al.21.
Detecting selection in CNVs
ASCAT raw copy number values were used to detected frequently deleted or amplified 
regions of the genome using GISTIC2.014. To determine which genes in these regions 
confer a selective advantage, CNVs from each gene within GISTIC identified loci were 
correlated with TPM from matched RNA-seq in a sub-cohort of 116 samples and with 
mutations across all 551 samples. To call copy number in genes that spanned multiple copy 
number segments in ASCAT, we considered the total number of full copies of the gene (i.e. 
the lowest total copy number). Occasionally ASCAT is unable to confidently call the copy 
number in highly aberrant genomic regions. We found that the expression of genes in such 
regions matched well what we would expect given the surrounding copy number, and hence 
we used the mean of the two adjacent copy number fragments to call copy number in the 
gene in question. We found amplification peak regions identified by GISTIC2.0 varied 
significantly in precise location both in analysis of different sub-cohorts and when 
comparing to published GISTIC data from EACs9,15,16. A peak would often sit next to but 
not overlapping a well-characterized oncogene or tumor suppressor. To account for this, we 
widened the amplification peak sizes upstream and downstream by twice the size of each 
peak to ensure we captured all possible drivers. Our expression analysis allows us to then 
remove false positives from this wider region, and called drivers were still highly enriched 
for genes closer to the centre of GISTIC peak regions.
To detect genes in which amplification correlated with increased expression, we compared 
expression of samples with a high copy number for that gene (above 10th percentile CN/
ploidy) with those that have a normal copy number (median +/- 1) using the Wilcoxon rank-
sum test and using the specific alternative hypothesis that high copy number would lead to 
increased expression. q-values were then generated based on the Benjamini and Hochberg 
method, not considering genes without significant expression in amplified samples (at least 
75% amplified samples with TPM > 0.1) and considering q < 0.001 as significant. We also 
included an additional known driver gene only FDR reduction analysis as previously 
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described for mutational drivers, with q < 0.1 considered as significant given the additional 
evidence for these genes in other cancer types. We also included MYC despite its P = 0.11 
for expression correlation. This is due to frequent non-amplification associated 
overexpression of MYC when compared to normal controls, and otherwise MYC is well 
evidenced by a very close proximity to the peak centre (top 4 genes) and its high rate of 
amplification (19%). We took the same approach to detect genes in which homozygous 
deletion correlated with expression loss, comparing cases with copy number = 0 to all 
others. Large expression modulation was a highly specific marker for known copy number 
driver genes and was not a widespread feature in most recurrently copy number variant 
genes. However, while expression modulation is a requirement for selection of CNV only 
drivers, it is not sufficient evidence alone, and hence we grouped such genes into those 
which have been characterized as drivers previously in other cancer types (high confidence 
EAC copy number drivers) and other genes (candidate EAC copy number drivers), which 
await functional validation. We used fragile site regions detected in Wala et al.56. We also 
defined regions that may be recurrently heterozygous deleted, without any significant 
expression modulations, to allow LOH of tumor suppressor gene mutations. To do this, we 
analyzed genes with at least 5 mutations for association between LOH (ASCAT minor allele 
= 0) and mutation using Fisher’s exact test and generated q values using the Benjamini and 
Hochberg method. The analysis was repeated on known cancer genes only for reduced FDR 
and q < 0.1 considered significant for both analyses. For those high confidence drivers, we 
chose to define amplification as total copy number/ploidy (referred to as ploidy adjusted 
copy number) because this produces superior correlation with expression. We chose a cut off 
for amplification at ploidy adjusted copy number = 2 as has been previously used, and 
causes a highly significant increase in expression in our copy number-driver genes when 
amplified.
Pathways and relative distributions of genomic events
The relative distribution of driver events in each pathway was analysed using a Fisher’s 
exact test in the case of pair-wise comparisons including wild-type cases. In the case of 
multi-gene comparisons such as cyclins, we calculate the P value and odds ratio for gene in 
the group using a two-sided Fisher’s exact test, corrected by Benjamini and Hochberg, and 
combine resulting q values using the Fisher method; genes without odds ratios > 2 for co-
occurrence and < 0.5 for mutual exclusivity were removed. For this analysis, we also remove 
highly mutated cases (>500 exonic mutations, 41/551) as they bias distribution of genes 
towards co-occurrence. To ensure that a non-random distribution of mutations across 
samples was still not affecting the strong co-occurrence of SWI/SNF genes (all genes q < 
0.05 before combining q values), we repeated the analysis randomly iterating 30,000 times 
over other driver gene eight combinations (excluding SWI/SNF genes) and found only 
0.01% (4/30,000) of random combinations had all genes q < 0.05 as found in SWI/SNF 
genes. We then performed this analyses across all pairs of driver genes using two sided 
Fisher’s exact tests and Benjamini and Hochberg multiple hypothesis correction (q values < 
0.1 are shown in Fig. 4b). We validated these relationships in independent TGCA cohorts of 
other GI cancers where we could find cohorts with reasonable numbers of the genomic 
events in question (not possible for GATA4/GATA6, for instance) using the cBioportal web 
interface tool57.
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Correlating genomics with the clinical phenotype
To find genomic markers for prognosis, we undertook univariate Cox regression for those 
driver genes present in >5% of cases (n = 16) along with Benjamini and Hochberg false 
discovery correction. We considered only these genes to reduce our false discovery rate and 
because other genes were unlikely to impact on clinical practice given their low frequency in 
EAC. We validated SMAD4 in the TCGA gastroesophageal cohort, which had a comparable 
frequency of these events, but notably is composed mainly of gastric cancers, and GATA4 in 
the TCGA pancreatic cohort using the cBioportal web interface tool. We also validated these 
markers as independent predictors of survival both in respect of each other and stage using a 
multivariate Cox regression in our 379 clinical annotated ICGC cohort. When assessing for 
genomic correlates with differentiation phenotypes, we found only very few cases with well 
differentiated phenotypes (<5% cases), and hence for statistical analyses, we collapse these 
cases with moderate differentiation to allow a binary Fisher’s exact test to compare poorly 
differentiated with well-moderate differentiated phenotypes.
Therapeutics
The cancer biomarker database was filtered for drugs linked to biomarkers found in EAC 
drivers, and Supplementary Table 8 was constructed using the cohort frequencies of EAC 
biomarkers. Ten EAC cell lines (SKGT4, OACP4C, OACM5.1, ESO26, ESO51, OE33, 
MFD, OE19, Flo-1 and JHesoAD) and three Barrett’s esophagus high grade dysplasia cell 
lines (CP-B, CP-C and CP-D) with WGS data41 were used in proliferation assays to 
determine drug sensitivity to CDK4/6 inhibitors, Palbociclib (Biovision) and Ribociclib 
(Selleckchem). Cell lines were grown in their normal growth media. Proliferation was 
measured using the Incucyte live cell analysis system (Incucyte ZOOM Essen biosciences). 
Each cell line was plated at a starting confluency of 10% and growth rate measured across 
4-7 days depending on basal proliferation rate (until 90% confluent). For each cell-line drug 
combination, concentrations of 16, 64, 250, 1,000 and 4,000 nM were used each in 0.3% 
DMSO and compared to 0.3% DMSO only. Each condition was performed in at least 
triplicate (technical replicates) and 12/12 randomly chosen cell line; drug combinations were 
successfully replicated with biological replicates (independent experiments). The time 
period of treatment to growth cessation in the control (0.3% DMSO) condition was used to 
calculate GI50 and AUC. Accurate GI50s could not be calculated in cases where a cell line 
had >50% proliferation inhibition even with the highest drug concentration, and hence AUC 
was used to compare cell line sensitivity. T47D had a highly similar GI50 for Palbociclib to 
that previously calculated in other studies (112 nM vs. 127 nM)58. Primary organoid 
cultures were derived from EAC cases included in the OCCAMS/ICGC sequencing study. 
Detailed organoid culture and derivation method have been previously described44. 
Regarding the drug treatment, the seeding density for each organoid line was optimized to 
ensure cell growth in the logarithmic growth phase. Cells were seeded in complete medium 
for 24 hours then treated with compounds at 5-point 4-fold serial dilutions for 6 days or 12 
days. Cell viability was assessed using CellTiter-Glo (Promega) after drug incubation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Genomic analysis of 551 esophageal adenocarcinomas identifies new driver mutations 
and biomarkers associated with poor prognosis. Over 50% of esophageal 
adenocarcinomas contain sensitizing events for CDK4/6 inhibitors, providing an evidence 
base for targeted therapeutics.
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Figure 1. Detection of EAC driver genes.
a, Types of driver-associated features used to detect positive selection in mutations and copy 
number events with examples of genes containing such features. b, Coding driver genes 
identified and their driver-associated features. c, Non-coding driver elements detected and 
their element types.
Frankell et al. Page 19













Figure 2. Copy number variation under positive selection.
a, Recurrent copy number changes across the genome identified by GISTIC in 551 EACs. 
Frequency of different CNV types are indicated (dark blue, homozygous deletion; light blue, 
heterozygous deletion; dark red, extrachromosomal-like amplification; light red, 
amplification) as well as the position of CNV high confidence driver genes and candidate 
driver genes. The q value for expression correlation with amplification and homozygous 
deletion is shown for each gene within each amplification (wilcox test, one sided, expression 
compared above and below 90th percentile of pliody-adjusted CN) and deletion peak 
(wilcox test, one sided, expression compared between homozygous deleted and all other 
cases) respectively and occasions of significant association between LOH and mutation are 
indicated in green (fisher’s exact test, one sided). Benjamini & Hochberg false discovery 
correction was applied in each of these cases. Purple deletion peaks indicate fragile sites. b, 
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Examples of extrachromosomal-like amplifications suggested by very high read support SVs 
at the boundaries of highly amplified regions produced from a single copy number step. In 
the first example two populations of extrachromosomal DNA are apparent, one amplifying 
only MYC and the second also incorporating ERBB2 from a different chromosome. In the 
second example an inversion has occurred before circularization and amplification around 
KRAS. c, Relationship between copy number and expression in copy number driver genes in 
RNA matched sub-cohort (n=116). A 2D kernel density estimation and a leoss regression 
curve with 95% CIs (grey) are shown to describe the data.
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Figure 3. The driver gene landscape of EAC.
a, Driver mutations or CNVs are shown for each patient of 551 EACs. Amplification is 
defined as >2 copy number adjusted ploidy (2x ploidy of that case) and extrachromosomal 
amplification as >10 copy number adjusted ploidy (10x ploidy for that case). Driver 
associated features for each driver gene are displayed to the left. On the right, the 
percentages of different mutation and copy number changes are displayed, differentiating 
between driver and passenger mutations using dNdScv, and the % of predicted drivers by 
mutation type is shown. Above the plot are the number of driver mutations per sample with 
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an indication of the mean (red line = 5). b, Mean driver events per case in 551 EACsand 
comparison to exome-wide excess of mutations generated by dNdScv. c, Expression changes 
in EAC driver genes in comparison to normal intestinal tissues in RNA matched samples 
(n=116). Only genes with expression changes of note are shown.
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Figure 4. Biological pathways undergoing selective dysregulation in EAC.
a, Biological pathways dysregulated by driver gene mutation and/or CNVs in 551 cases. 
Wild-type cases for a pathway are not shown. Inter and intra-pathway interactions are 
described, and mutual exclusivities and/or associations between genes in a pathway are 
annotated. GATA4 and GATA6 amplifications have a mutually exclusive relationship, 
although this does not reach statistical significance (Fisher’s exact test, two-sided, P = 0.07, 
OR = 0.52). b, Pairwise assessment of mutual exclusivity and association in EAC driver 
genes and pathways. Two sided Fisher’s exact test were used and hyper-mutated (>500 
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exonic mutations) cases were removed to avoid bias towards co-occurrence, hence n = 510. 
RTK; Receptor Tyrosine Kinase pathway.
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Figure 5. Clinical significance of driver events in 379 clinically annotated EACs.
a, Hazard ratios and 95% confidence intervals for Cox regression analysis across all driver 
genes with at least a 5% frequency of driver alterations. *q < 0.05 after BH adjustment. b, 
Kaplan-Meier curves for EACs with different status of significant prognostic indicators 
(GATA4 and SMAD4). c, Kaplan-Meier curves for different alterations in the TGF-β 
pathway. d, Kaplan-Meier curves showing verification GATA4 prognostic value in GI 
cancers using a pancreatic TCGA cohort. e, Kaplan-Meier curves showing verification 
SMAD4 prognostic value in gastroesophageal cancers using a gastroesophageal TCGA 
cohort. f, Differentiation bias in tumors containing events in Wnt pathway driver genes. g, 
Relative frequency of KRAS mutations and TP53 mutations driver gene events in females 
vs. males (Fisher’s exact test, two sided).
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Figure 6. CDK4/6 inhibitors in EAC.
a, Drug classes for which sensitivity is indicated by EAC driver genes with data from the 
Cancer Biomarkers database36. b, Area under the curve (AUC) of sensitivity is shown in a 
panel of 13 EAC and Barrett’s esophagus high grade dysplasia cell lines with associated 
WGS and their corresponding driver events, based on primary tumor analysis. AUC is also 
shown for two control lines: T47D, an ER-positive breast cancer line (positive control), and 
MDA-MB-468, an Rb negative breast cancer (negative control). *CCNE1 is a known marker 
of resistance to CDK4/6 inhibitors due to its regulation of Rb downstream of CDK4/6, hence 
bypassing the need for CDK4/6 activity (see Fig. 4). c, Response of organoid cultures to 
three FDA approved CDK4/6 inhibitors and corresponding driver events. RTK; Receptor 
tyrosine kinase pathway, BC; Breast Cancer.
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